http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020306372-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72192b485edb2254e5fa13f023bd4de4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001121 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2019-11-01^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_306400f09f9c7315a220f3b31ae2033a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_178a5358b9b902fab8def7d23558ddc9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4aa372dbb932177c2cb2760dd7767300 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2bf23f5bc15b9fffbcd513c58587c3e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b9ec2deee3640ee2980c24bf3c4cb29 |
| publicationDate | 2020-10-01^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020306372-A1 |
| titleOfInvention | Methods for reducing viral load in hiv-1 infected patients |
| abstract | This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log10 to 2.5 log10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log10 at about nine days following administration of the CCR5 receptor antagonist. The viral load reducing dose results in a suppression of mean viral load by 1.0 log10 within about four days following administration of the CCR5 receptor antagonist, and suppression of viral load in the subject persists at or below a level of reduction of 1.0 log10 for about two to three weeks. This invention also provides a method of elevating CD4+ cell count in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval an effective HIV-1 viral load-reducing dose of a humanized antibody designated PRO 140, or an anti-CCR5 receptor monoclonal antibody. |
| priorityDate | 2008-04-30^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 515 of 515.